CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced a three-way collaboration with Horizon Healthcare Services, Inc., New Jersey’s oldest and largest health insurer, and Clinical Outcomes Tracking and Analysis (COTA) to advance precision medicine, improve clinical outcomes and deliver enhanced value to the healthcare system in the treatment of patients with metastatic, non-small cell lung cancer (NSCLC). The organizations initiated a prospective clinical study measuring changes in survival benefit and total cost savings achieved among patients with previously untreated metastatic NSCLC who undergo comprehensive genomic profiling with FoundationOne®. Based on the outcomes, the study enables Horizon to provide its members with coverage for FoundationOne as a critical component of clinical care pathways in the evaluation of patients with metastatic lung cancer.
